AJANTPHARM2024-10-012024-12-31 AJANTPHARM2024-10-012024-12-31 AJANTPHARM2024-10-012024-12-31in-bse-fin:OneOperatingExpenses01Member AJANTPHARM2024-10-012024-12-31in-bse-fin:FourOperatingExpenses01Member AJANTPHARM2024-12-31 iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 532331 AJANTPHARM NOTLISTED Ajanta Pharma Limited Equity 2024-04-01 2025-03-31 2025-01-30 2025-01-17 INR Crores Third quarter 13:30:00 15:20:00 2025-01-30 2025-01-30 Not applicable Single segment PHARMACEUTICAL 2024-10-01 2024-12-31 Unaudited Standalone 11019200000.00 332300000.00 11351500000.00 2101400000.00 402300000.00 40000000.00 2457100000.00 24800000.00 349300000.00 2655100000.00 8030000000.00 3321500000.00 0.00 3321500000.00 763800000.00 33200000.00 797000000.00 0.00 2524500000.00 0.00 0.00 0.00 0.00 2524500000.00 -4100000.00 2520400000.00 2520400000.00 0.00 250700000.00 2 20.16 20.15 0.00 0.00 20.16 20.15 1. The above standalone results have been reviewed by Audit Committee and approved by the Board of Directors at their meeting held on 30 January 2025. The statutory auditors have expressed an unmodified opinion on the results for the quarter and nine month period ended 31 December 2024. The review report has been filed with the stock exchange and is available on company website. 2.Other income / Other expense includes:- Rs in Crore Particular Quarter ended Nine Month ended Year ended 31-Dec-24 30-Set-24 31-Dec-23 31-Dec-24 31-Dec-23 31-Mar-24 Dividend from Subsidiaries - 22.28 - 22.28 29.13 29.13 (in other income) Foreign exchange gain 20.72 10.95 3.63 30.73 24.89 43.16 (in other income) Foreign exchange loss - 25.65 7.58 13.88 - - (in other expenses) 3. During nine month ended 31 December 2024, 25,325 (previous year 1,000) equity shares of Rs 2 each, fully paid up, were allotted upon exercise of vested options pursuant to the Share Based Incentive Plan, 2019, resulting in an increase in the paid-up share capital by Rs 50,650 (previous year Rs 2,000) and securities premium by Rs 3.84 crores (previous year Rs 0.18 crores). 4. On 2 May 2024, Company has announced buy back of its 10,28,881 equity shares, being 0.82% of the total paid up equity share capital at Rs. 2,770 per equity share for an aggregate amount of Rs. 285.00 crores. The buyback opened on 05 June 2024, closed on 11 June 2024 and Company extinguished those shares on 27 June 2024. 5.The Company operates exclusively in one reportable business segment i.e., Pharmaceuticals . 6. The Financial Results are available for investors on the company's website www.ajantapharma.com and stock exchange websites www.nseindia.com and www.bseindia.com. Single segment 2024-04-01 2024-12-31 Unaudited Standalone 33081000000.00 1019400000.00 34100400000.00 6556400000.00 1274600000.00 -34800000.00 7530400000.00 39300000.00 1011700000.00 8203700000.00 24581300000.00 9519100000.00 0.00 9519100000.00 2189300000.00 95200000.00 2284500000.00 0.00 7234600000.00 0.00 0.00 0.00 0.00 7234600000.00 -44000000.00 7190600000.00 7190600000.00 0.00 250700000.00 2 57.79 57.76 0.00 0.00 57.79 57.76 Other expenses 2655100000.00 Other expenses 8203700000.00 -6300000.00 -67700000.00 -2200000.00 -23700000.00 0.00 0.00